Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480

Figure 2 Effect of TRAIL and doxorubicin on SW480 cells. SW480 cells were treated with doxorubicin alone or a combination of doxorubicin with TRAIL at different concentrations. The combination resulted in the reduction of doxorubicin IC₅₀ in cells (P < 0.05). Doxorubicin IC₅₀ was 65.25 ± 3.48 when cells were treated by doxorubicin alone, while it was further reduced with the increased concentrations of TRAIL. Doxorubicin IC₅₀ was 43.17 ± 2.54 μmol•l^-1 when it was combined with 10 mg•l^-1of TRAIL, 0.51 ± 0.02 μmol•l^-1IC₅₀ when combined with 100 μg•l^-1 TRAIL, and 0.44 ± 0.02 μmol•l^-1 IC₅₀ when combined with 1000 μg•l^-1TRAIL.